Study on effectiveness of bevacizumab for treatment of radiation necrosis in the brain caused by gamma knife radiation therapy

Study on effectiveness of bevacizumab for treatment of radiation necrosis in the brain caused by gamma knife radiation therapy - Bevacizumab for brain radiation necrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034959

Enrollment

Registered

2018-11-26

Start date

2016-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiation necrosis in the brain

Interventions

administration of bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: radiation necrosis in the brain caused by gamma knife radiation therapy

Exclusion criteria

Exclusion criteria: Association of contraindication of bevacizumab

Design outcomes

Primary

Measure	Time frame
Improvement of symptoms and MRI findings 2 years after initial treatment with bevacizumab.	—

Secondary

Measure	Time frame
1)Safety 2)re-exacerbation with 2 years after initial treatment with bevacizumab.	—

Countries

Japan

Contacts

Public ContactTakao Hashimoto

Aizawa Hospital Department of Neurology

sinke-dr@ai-hosp.or.jp0263338600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026